Richard Cone
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$12.2MFederal grants as PI21 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
21 awards · $12.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Feb 14, 2024 | NIH | SBIR Phase II SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | $1.0M | MUCOMMUNE, LLC |
| Aug 22, 2023 | NIH | SBIR Phase II IND‐enabling development of MM‐008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring | $1.0M | MUCOMMUNE, LLC |
| Mar 16, 2023 | NIH | SBIR Phase II SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | $1.0M | MUCOMMUNE, LLC |
| Sep 19, 2022 | NIH | SBIR Phase II IND‐enabling development of MM‐008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring | $1.0M | MUCOMMUNE, LLC |
| May 3, 2022 | NIH | SBIR Phase II Development of RespiraClear for targeted mucosal treatment of RSV infections | $892K | MUCOMMUNE, LLC |
| Sep 7, 2021 | NIH | SBIR Phase II In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring | $757K | MUCOMMUNE, LLC |
| Aug 1, 2021 | NIH | SBIR Phase I Multipurpose vaginal ring for non-hormonal contraception and preventing bacterial vaginosis | $266K | MUCOMMUNE, LLC |
| May 7, 2021 | NIH | SBIR Phase II Development of RespiraClear for targeted mucosal treatment of RSV infections | $658K | MUCOMMUNE, LLC |
| Mar 4, 2021 | NIH | SBIR Phase II SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | $307K | MUCOMMUNE, LLC |
| Mar 1, 2021 | NIH | SBIR Phase I Vaginal ring for sustained release of lactic acid to prevent bacterial vaginosis and associated health risks | $307K | MUCOMMUNE, LLC |
| Nov 27, 2020 | NIH | SBIR Phase II In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV | $996K | MUCOMMUNE, LLC |
| Sep 15, 2020 | NIH | SBIR Phase II In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring | $973K | MUCOMMUNE, LLC |
| Jun 23, 2020 | NIH | SBIR Phase I Inhaled 'muco-trapping' antibody as universal immunotherapy for influenza virus infections | $275K | MUCOMMUNE, LLC |
| Jun 22, 2020 | NIH | SBIR Phase I Aerosol immunotherapy for treatment of human metapneumovirus infection | $262K | MUCOMMUNE, LLC |
| Dec 23, 2019 | NIH | SBIR Phase II In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV | $999K | MUCOMMUNE, LLC |
| Aug 19, 2019 | NIH | SBIR Phase II Development of RespiraClear for targeted mucosal treatment of RSV infections | $225K | MUCOMMUNE, LLC |
| Jan 26, 2019 | NIH | SBIR Phase I Non-hormonal contraception based on vaginal delivery of multimeric sperm-binding antibodies | $225K | MUCOMMUNE, LLC |
| Sep 17, 2018 | NIH | SBIR Phase II Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | $225K | MUCOMMUNE, LLC |
| Aug 17, 2018 | NIH | SBIR Phase I Nebulized 'muco-trapping' antibodies for treating respiratory syncytial virus (RSV) infections | $225K | MUCOMMUNE, LLC |
| Jul 8, 2018 | NIH | SBIR Phase I Development of a biologic for non-hormonal contraception | $213K | MUCOMMUNE, LLC |
| May 7, 2018 | NIH | SBIR Phase I Sustained vaginal delivery of monoclonal antibodies for preventing HIV transmission | $225K | MUCOMMUNE, LLC |
Peer ranks
Federal funding#38
Awards as PI#14
Patents#273
Companies
- MUCOMMUNE, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.